PF-4var/CXCL4L1 Predicts Outcome in Stable Coronary Artery Disease Patients with Preserved Left Ventricular Function

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Mar 3

PMID 22384011

Citations 7

Authors

Johan De Sutter

Nico R van de Veire

Sofie Struyf

Jan Philippe

Marc De Buyzere

Jo Van Damme

Affiliations

Soon will be listed here.

Abstract

Background: Platelet-derived chemokines are implicated in several aspects of vascular biology. However, for the chemokine platelet factor 4 variant (PF-4var/CXCL4L1), released by platelets during thrombosis and with different properties as compared to PF-4/CXCL4, its role in heart disease is not yet studied. We evaluated the determinants and prognostic value of the platelet-derived chemokines PF-4var, PF-4 and RANTES/CCL5 in patients with stable coronary artery disease (CAD).

Methodology/principal Findings: From 205 consecutive patients with stable CAD and preserved left ventricular (LV) function, blood samples were taken at inclusion and were analyzed for PF-4var, RANTES, platelet factor-4 and N-terminal pro-B-type natriuretic peptide (NT-proBNP). Patients were followed (median follow-up 2.5 years) for the combined endpoint of cardiac death, non-fatal acute myocardial infarction, stroke or hospitalization for heart failure. Independent determinants of PF-4var levels (median 10 ng/ml; interquartile range 8-16 ng/ml) were age, gender and circulating platelet number. Patients who experienced cardiac events (n = 20) during follow-up showed lower levels of PF-4var (8.5 [5.3-10] ng/ml versus 12 [8-16] ng/ml, p = 0.033). ROC analysis for events showed an area under the curve (AUC) of 0.82 (95% CI 0.73-0.90, p<0.001) for higher NT-proBNP levels and an AUC of 0.32 (95% CI 0.19-0.45, p = 0.009) for lower PF-4var levels. Cox proportional hazard analysis showed that PF-4var has an independent prognostic value on top of NT-proBNP.

Conclusions: We conclude that low PF-4var/CXCL4L1 levels are associated with a poor outcome in patients with stable CAD and preserved LV function. This prognostic value is independent of NT-proBNP levels, suggesting that both neurohormonal and platelet-related factors determine outcome in these patients.

Citing Articles

A Multi-Omics Approach to Defining Target Organ Injury in Youth with Primary Hypertension.

Ananthamohan K, Brady T, Arif M, Daniels S, Falkner B, Ferguson M bioRxiv. 2024; .

PMID: 38948714 PMC: 11212900. DOI: 10.1101/2024.06.17.599125.

Heterocomplexes between the atypical chemokine MIF and the CXC-motif chemokine CXCL4L1 regulate inflammation and thrombus formation.

Brandhofer M, Hoffmann A, Blanchet X, Siminkovitch E, Rohlfing A, El Bounkari O Cell Mol Life Sci. 2022; 79(10):512.

PMID: 36094626 PMC: 9468113. DOI: 10.1007/s00018-022-04539-0.

Differential Effects of Platelet Factor 4 (CXCL4) and Its Non-Allelic Variant (CXCL4L1) on Cultured Human Vascular Smooth Muscle Cells.

Kaczor D, Kramann R, Hackeng T, Schurgers L, Koenen R Int J Mol Sci. 2022; 23(2).

PMID: 35054772 PMC: 8775478. DOI: 10.3390/ijms23020580.

Proteomics: A promising approach to discover new biomarkers for atrial fibrillation.

Song J, Dobrev D, Li N Int J Cardiol. 2021; 345:125-126.

PMID: 34710496 PMC: 8876401. DOI: 10.1016/j.ijcard.2021.10.135.

Chemokine-Induced Macrophage Polarization in Inflammatory Conditions.

Ruytinx P, Proost P, Van Damme J, Struyf S Front Immunol. 2018; 9:1930.

PMID: 30245686 PMC: 6137099. DOI: 10.3389/fimmu.2018.01930.

References

Slungaard A, Fernandez J, Griffin J, Key N, Long J, Piegors D . Platelet factor 4 enhances generation of activated protein C in vitro and in vivo. Blood. 2003; 102(1):146-51. DOI: 10.1182/blood-2002-11-3529. View

Vandercappellen J, Van Damme J, Struyf S . The role of the CXC chemokines platelet factor-4 (CXCL4/PF-4) and its variant (CXCL4L1/PF-4var) in inflammation, angiogenesis and cancer. Cytokine Growth Factor Rev. 2010; 22(1):1-18. DOI: 10.1016/j.cytogfr.2010.10.011. View

Petersen F, Bock L, Flad H, Brandt E . A chondroitin sulfate proteoglycan on human neutrophils specifically binds platelet factor 4 and is involved in cell activation. J Immunol. 1998; 161(8):4347-55. View

Han Z, Bellucci S, Tenza D, Caen J . Negative regulation of human megakaryocytopoiesis by human platelet factor 4 and beta thromboglobulin: comparative analysis in bone marrow cultures from normal individuals and patients with essential thrombocythaemia and immune thrombocytopenic.... Br J Haematol. 1990; 74(4):395-401. DOI: 10.1111/j.1365-2141.1990.tb06325.x. View

Woller G, Brandt E, Mittelstadt J, Rybakowski C, Petersen F . Platelet factor 4/CXCL4-stimulated human monocytes induce apoptosis in endothelial cells by the release of oxygen radicals. J Leukoc Biol. 2008; 83(4):936-45. DOI: 10.1189/jlb.0907592. View

Lasagni L, Grepin R, Mazzinghi B, Lazzeri E, Meini C, Sagrinati C . PF-4/CXCL4 and CXCL4L1 exhibit distinct subcellular localization and a differentially regulated mechanism of secretion. Blood. 2007; 109(10):4127-34. DOI: 10.1182/blood-2006-10-052035. View

Schnabel R, Schulz A, Messow C, Lubos E, Wild P, Zeller T . Multiple marker approach to risk stratification in patients with stable coronary artery disease. Eur Heart J. 2010; 31(24):3024-31. DOI: 10.1093/eurheartj/ehq322. View

Gleissner C, Shaked I, Little K, Ley K . CXC chemokine ligand 4 induces a unique transcriptome in monocyte-derived macrophages. J Immunol. 2010; 184(9):4810-8. PMC: 3418140. DOI: 10.4049/jimmunol.0901368. View

Coelho A, Hogaboam C, Kunkel S . Chemokines provide the sustained inflammatory bridge between innate and acquired immunity. Cytokine Growth Factor Rev. 2005; 16(6):553-60. DOI: 10.1016/j.cytogfr.2005.03.004. View

10.

Struyf S, Burdick M, Peeters E, Van den Broeck K, Dillen C, Proost P . Platelet factor-4 variant chemokine CXCL4L1 inhibits melanoma and lung carcinoma growth and metastasis by preventing angiogenesis. Cancer Res. 2007; 67(12):5940-8. DOI: 10.1158/0008-5472.CAN-06-4682. View

11.

Koenen R, von Hundelshausen P, Nesmelova I, Zernecke A, Liehn E, Sarabi A . Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med. 2009; 15(1):97-103. DOI: 10.1038/nm.1898. View

12.

Struyf S, Burdick M, Proost P, Van Damme J, Strieter R . Platelets release CXCL4L1, a nonallelic variant of the chemokine platelet factor-4/CXCL4 and potent inhibitor of angiogenesis. Circ Res. 2004; 95(9):855-7. DOI: 10.1161/01.RES.0000146674.38319.07. View

13.

Struyf S, Salogni L, Burdick M, Vandercappellen J, Gouwy M, Noppen S . Angiostatic and chemotactic activities of the CXC chemokine CXCL4L1 (platelet factor-4 variant) are mediated by CXCR3. Blood. 2010; 117(2):480-8. PMC: 3031477. DOI: 10.1182/blood-2009-11-253591. View

14.

Mueller A, Meiser A, McDonagh E, Fox J, Petit S, Xanthou G . CXCL4-induced migration of activated T lymphocytes is mediated by the chemokine receptor CXCR3. J Leukoc Biol. 2008; 83(4):875-82. DOI: 10.1189/jlb.1006645. View

15.

Rudiger A, Fischler M, Harpes P, Gasser S, Hornemann T, von Eckardstein A . In critically ill patients, B-type natriuretic peptide (BNP) and N-terminal pro-BNP levels correlate with C-reactive protein values and leukocyte counts. Int J Cardiol. 2007; 126(1):28-31. DOI: 10.1016/j.ijcard.2007.03.108. View

16.

Lambert M, Rauova L, Bailey M, Sola-Visner M, Kowalska M, Poncz M . Platelet factor 4 is a negative autocrine in vivo regulator of megakaryopoiesis: clinical and therapeutic implications. Blood. 2007; 110(4):1153-60. PMC: 1976471. DOI: 10.1182/blood-2007-01-067116. View

17.

Bibbins-Domingo K, Gupta R, Na B, Wu A, Schiller N, Whooley M . N-terminal fragment of the prohormone brain-type natriuretic peptide (NT-proBNP), cardiovascular events, and mortality in patients with stable coronary heart disease. JAMA. 2007; 297(2):169-76. PMC: 2848442. DOI: 10.1001/jama.297.2.169. View

18.

Vandercappellen J, Noppen S, Verbeke H, Put W, Conings R, Gouwy M . Stimulation of angiostatic platelet factor-4 variant (CXCL4L1/PF-4var) versus inhibition of angiogenic granulocyte chemotactic protein-2 (CXCL6/GCP-2) in normal and tumoral mesenchymal cells. J Leukoc Biol. 2007; 82(6):1519-30. DOI: 10.1189/jlb.0407206. View

19.

Fricke I, Mitchell D, Petersen F, Bohle A, Bulfone-Paus S, Brandau S . Platelet factor 4 in conjunction with IL-4 directs differentiation of human monocytes into specialized antigen-presenting cells. FASEB J. 2004; 18(13):1588-90. DOI: 10.1096/fj.03-1435fje. View

20.

Charo I, Taubman M . Chemokines in the pathogenesis of vascular disease. Circ Res. 2004; 95(9):858-66. DOI: 10.1161/01.RES.0000146672.10582.17. View